BrainStorm Cell stock sinks following negative FDA adcomm vote on ALS drug

The FDA adcomm vote came days after Reuters reported that FDA staff reviewers raised concerns over the safety and efficacy of the ALS therapy.

Related Keywords

Chaim Lebovits ,Stacy Lindbord ,Drug Administration ,Advisory Committee ,Gene Therapies Advisory Committee ,Takeda Pharmaceuticals ,Maxim Group ,Reuters ,Ionis Pharmaceuticals ,Brainstorm Cell Therapeutic ,Amylyx Pharmaceutical Relyvrio ,